Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Early-stage HER2+ Breast Cancer”

291 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 291 results

Testing effectiveness (Phase 2)Study completedNCT00003992
What this trial is testing

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2

Who this might be right for
Breast Cancer
National Cancer Institute (NCI) 200
Testing effectiveness (Phase 2)Looking for participantsNCT05559164
What this trial is testing

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Who this might be right for
Cardiac ToxicityEarly-stage Breast Cancer
Rutgers, The State University of New Jersey 60
Testing effectiveness (Phase 2)Ended earlyNCT05180006
What this trial is testing

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy

Who this might be right for
Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 33
Testing effectiveness (Phase 2)Study completedNCT02789332
What this trial is testing

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

Who this might be right for
Breast CancerTriple Negative Breast NeoplasmsHRpos Breast Neoplasms+1 more
GBG Forschungs GmbH 107
Testing effectiveness (Phase 2)UnknownNCT04997798
What this trial is testing

Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer

Who this might be right for
Breast CancerEstrogen Receptor Positive TumorHER2-positive Breast Cancer
First Affiliated Hospital of Zhejiang University 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225
What this trial is testing

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Who this might be right for
Breast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Testing effectiveness (Phase 2)UnknownNCT04247633
What this trial is testing

High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)

Who this might be right for
Breast Cancer
Samsung Medical Center 578
Large-scale testing (Phase 3)Study completedNCT00490139
What this trial is testing

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 8,381
Not applicableNot Yet RecruitingNCT07098507
What this trial is testing

De-escalation in Axillary Surgery for Early-stage Breast Cancer

Who this might be right for
Omitting Sentinel Lymph Node Biopsy in Early-stage Breast Cancer
Clinical Hospital Center Rijeka 620
Testing effectiveness (Phase 2)UnknownNCT04499118
What this trial is testing

AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer

Who this might be right for
HER2-negative Breast Cancer
Sichuan Provincial People's Hospital 100
Large-scale testing (Phase 3)Active Not RecruitingNCT05346224
What this trial is testing

Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmsHER2-positive Breast Cancer
Shanghai Henlius Biotech 900
Large-scale testing (Phase 3)Active Not RecruitingNCT04964934
What this trial is testing

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 315
Testing effectiveness (Phase 2)Looking for participantsNCT06797635
What this trial is testing

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Who this might be right for
Breast NeoplasmsBreast Cancer
Merck Sharp & Dohme LLC 372
Large-scale testing (Phase 3)Study completedNCT02162667
What this trial is testing

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

Who this might be right for
HER2-positive Carcinoma of Breast
Celltrion 562
Not applicableNot Yet RecruitingNCT06810492
What this trial is testing

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

Who this might be right for
Breast Cancer Stage IIIBreast Cancer Stage II
Hongmei Zheng, PhD 40
Large-scale testing (Phase 3)Study completedNCT01566721
What this trial is testing

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 2,577
Post-approval studies (Phase 4)UnknownNCT05036005
What this trial is testing

Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)

Who this might be right for
Breast CancerBreast NeoplasmsBreast Cancer Female+1 more
Institut fuer Frauengesundheit 108
Large-scale testing (Phase 3)Study completedNCT02194166
What this trial is testing

Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration

Who this might be right for
Breast Cancer
Hoffmann-La Roche 90
Not applicableLooking for participantsNCT07527741
What this trial is testing

Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization

Who this might be right for
Early-stage HER2+ Breast Cancer
Hoffmann-La Roche 100
Large-scale testing (Phase 3)Study completedNCT04629846
What this trial is testing

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Who this might be right for
Breast Cancer
Qilu Pharmaceutical Co., Ltd. 517
Load More Results